Controls extrapyramidal disorders (except tardive dyskinesia-see PRECAUTIONS ) due to…. ANDA 81265, held by Chartwell RX. Benztropine Mesylate.
As of Nov 22, 2026, ANDA 81265 (Benztropine Mesylate), held by Chartwell RX, was first approved by FDA on Jan 23, 1992, with 10 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Benztropine Mesylate Tablets, USP are indicated for use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia-see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 23, 1992 | Original application | Approved | None posted |
| Benztropine Mesylate2MG · tablet;oral | Benztropine Mesylate | Rx |
| Benztropine Mesylate1MG · tablet;oral | Benztropine Mesylate | Rx |
| Benztropine Mesylate0.5MG · tablet;oral | Benztropine Mesylate | Rx |
| May 15, 2002 | Supplement 10Labeling | Approved | None posted |
| May 16, 2000 | Supplement 9Manufacturing | Approved | None posted |
| May 16, 2000 | Supplement 8Manufacturing | Approved | None posted |
| Mar 25, 1998 | Supplement 7Labeling | Approved | None posted |
| Dec 5, 1997 | Supplement 6Manufacturing | Approved | None posted |
| Feb 24, 1997 | Supplement 5Manufacturing | Approved | None posted |
| Oct 31, 1996 | Supplement 4Manufacturing | Approved | None posted |
| Jun 22, 1995 | Supplement 3Manufacturing | Approved | None posted |
| Jan 12, 1994 | Supplement 2Manufacturing | Approved | None posted |
| Jul 6, 1993 | Supplement 1Labeling | Approved | None posted |
| Jan 23, 1992 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters